In Brief: Pharmacia & Upjohn's Motrin IB Sinus
This article was originally published in The Tan Sheet
Executive Summary
Pharmacia & Upjohn's Motrin IB Sinus: Will return to stores "within the next two to four weeks," the company says. The product will be reintroduced in 30-count "bonus packs" at a suggested average retail price of $4.37. Pharmacia & Upjohn took the ibuprofen/pseudoephedrine combination off the market about a year ago after losing a patent infringement suit filed against the company and McNeil by Rich-Vicks. The decision was reversed by a federal appellate court ruling ("The Tan Sheet" Jan. 22, p. 1). According to Pharmacia & Upjohn, Motrin IB Sinus had a 2.5% market share among "all sinus remedies" in 1994...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning